Tempus AI, Inc. (NASDAQ:TEM) is without doubt one of the 11 Best Performing IPOs in the Last 2 Years.
The inventory’s worth goal is raised following a robust second quarter and FDA approval for Tempus Pixel.
Copyright: argus456 / 123RF Stock Photo
On August 08, 2025, Tempus AI, Inc. (NASDAQ:TEM) reported a second-quarter 2025 income of $314.6 million, a rise of 89.6%. The expansion was attributed to a 115% improve in Genomics income pushed by sturdy oncology quantity progress. Later, on September 11, 2025, the corporate additionally introduced buying 510(ok) clearance from the U.S. Meals and Drug Administration (FDA) for its up to date Tempus Pixel. This AI-powered cardiac imaging platform’s new replace permits the era of T1 and T2 inline maps, thus optimizing the system’s capabilities for cardiac MR picture evaluation.
Following these developments, H.C. Wainwright raised the inventory’s worth goal from $90 to $98, whereas sustaining the Purchase score, signaling an upside potential for the inventory. Since its IPO, the corporate has achieved a notable progress of 111.50%, including to its optimistic outlook.
Tempus AI, Inc. (NASDAQ:TEM) was based in 2015 and is headquartered in Illinois. Established beneath the healthcare know-how sector, the corporate is a pacesetter in making use of synthetic intelligence to medical and molecular information to advance precision drugs, thus creating more practical remedies for sufferers.
Whereas we acknowledge the potential of TEM as an funding, we consider sure AI shares supply better upside potential and carry much less draw back danger. For those who’re in search of an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the best short-term AI stock.
READ NEXT: 13 Best Freight Stocks to Invest in Now and 12 Jim Cramer Stock Picks this Week
Disclosure. None.
